Osiris Therapeutics (NASDAQ:OSIR) Options Ratio

Osiris Therapeutics, Inc. (NASDAQ:OSIR) lost -5% today, but their Put to Call ratio in May is making me think it's time to buy.

Open interest on the May calls total 1,917 while put volume is 1,007.

Strike Symbol Last Chg Bid Ask Vol Open Int 2.50 QIU100522C00002500 4.30 0.00 5.20 5.90 0 20 5.00 QIU100522C00005000 3.40 0.00 2.75 3.10 5 21 7.50 QIU100522C00007500 1.10  0.60 0.95 1.20 5 538 10.00 QIU100522C00010000 0.20  0.10 0.20 0.30 21 1,264 12.50 QIU100522C00012500 0.15 0.00 N/A 0.20 0 74

Strike Symbol Last Chg Bid Ask Vol Open Int 5.00 QIU100522P00005000 0.20  0.05 N/A 0.20 40 218 7.50 QIU100522P00007500 0.85  0.30 0.60 0.85 40 641 10.00 QIU100522P00010000 1.70 0.00 2.25 2.70 0 122 12.50 QIU100522P00012500 4.30 0.00 4.40 5.10 0 26

Meanwhile, Sunlight Research is releasing a report on Osiris' Patents:

Stem cell therapies covered by the Osiris patent claims are currently undergoing clinical trials for evaluation as biologic drug candidates for inflammatory bowel diseases, diabetes, graft versus host disease and cardiovascular disease.  Osiris may soon initiate clinical trials for other diseases, including arthritis.

Daniel A. Halpern, President of Sunlight Research observed, "Osiris is a key player in stem cell therapies, it has developed a leading patent portfolio, and has collaboration agreements with Genzyme, the U.S. Department of Defense and the Juvenile Diabetes Research Foundation.  Understanding the strengths and limitations of Osiris' intellectual property is critical for those competing in this space."  Osiris reported  $40.0 million in revenue last year from its collaboration agreement with Genzyme.  Halpern added that "industry professionals involved in patents, licensing, business development, investment analysis and others interested in the evolving stem cell therapy sector or concerned about patent infringement risk and competitive threats in this field will find this to be a valuable resource."

You can buy the report for the insane price of just $1,850 on Sunlight Research's website